A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC)- Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.262
https://www.valueinhealthjournal.com/article/S1098-3015(17)30596-X/fulltext
Title :
A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC)- Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30596-X&doi=10.1016/j.jval.2017.08.262
First page :
A444
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
242